Literature DB >> 22212103

Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study.

David Gyllenberg1, Andre Sourander.   

Abstract

BACKGROUND: Little is known about the timing of the start of psychotropic drug use and psychotropic polypharmacy use. AIMS: This study describes these patterns in a Finnish representative cohort aged between 12 and 25.
METHODS: 5525 subjects born in 1981 were followed up between 1994 and 2005 using the Finnish National Prescription Register.
RESULTS: Survival analysis revealed that the cumulative incidence of any psychotropic drug use was 1.3% by age 15, 6.1% by age 20 and 15.2% by age 25. Antidepressants and benzodiazepines were the most used drug groups, with cumulative incidences of 12.2% and 5.2%, respectively, by age 25. The cumulative incidence of polypharmacy was 0.02% by age 15, 0.9% by age 20 and 4.1% by age 25, i.e. having purchased at least two psychotropic drugs from different classes during the same day. Polypharmacy occurred among the majority of antipsychotic and benzodiazepine users, but among a minority of antidepressant users. More females than males had used any psychotropic drug, antidepressants, the antidepressant-benzodiazepine combination and the antidepressant-mood stabilizer combination.
CONCLUSIONS: Both general psychotropic drug use and psychotropic polypharmacy use was often started in late adolescence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22212103     DOI: 10.3109/08039488.2011.644809

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  9 in total

1.  [Validation of interaction databases in psychopharmacotherapy].

Authors:  M Hahn; S C Roll
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

2.  Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents.

Authors:  Greta A Bushnell; Stephen Crystal; Mark Olfson
Journal:  Am J Prev Med       Date:  2019-12       Impact factor: 5.043

Review 3.  Defining pediatric polypharmacy: A scoping review.

Authors:  Paul M Bakaki; Alexis Horace; Neal Dawson; Almut Winterstein; Jennifer Waldron; Jennifer Staley; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; Hannah Johnson; Negar Golchin; James A Feinstein; Shari D Bolen; Lawrence C Kleinman
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

4.  A whole of population retrospective observational study on the rates of polypharmacy in New Zealand 2014 to 2018 Polypharmacy in New Zealand: What is the current status?

Authors:  James Nind; Alesha Smith; Manjula Devananda; Benoit Auvray
Journal:  Health Sci Rep       Date:  2021-03-10

5.  Socioeconomic differences in psychiatric treatment before and after self-harm: an observational study of 4,280 adolescents and young adults.

Authors:  Joonas Pitkänen; Hanna Remes; Mikko Aaltonen; Pekka Martikainen
Journal:  BMC Psychiatry       Date:  2022-01-05       Impact factor: 3.630

6.  Mother's country of birth and prescription of psychotropic medication in Swedish adolescents: a life course approach.

Authors:  Willemijn Van Leeuwen; Sofia Nilsson; Juan Merlo
Journal:  BMJ Open       Date:  2012-09-14       Impact factor: 2.692

7.  Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning.

Authors:  K O'Sullivan; F Boland; U Reulbach; N Motterlini; D Kelly; K Bennett; T Fahey
Journal:  BMC Pediatr       Date:  2015-09-11       Impact factor: 2.125

8.  Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland.

Authors:  K O'Sullivan; U Reulbach; F Boland; N Motterlini; D Kelly; K Bennett; T Fahey
Journal:  BMJ Open       Date:  2015-06-09       Impact factor: 3.006

9.  Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.

Authors:  Anna Sidorchuk; Kayoko Isomura; Yasmina Molero; Clara Hellner; Paul Lichtenstein; Zheng Chang; Johan Franck; Lorena Fernández de la Cruz; David Mataix-Cols
Journal:  PLoS Med       Date:  2018-08-07       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.